Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir plus Ribavirin in Egyptian Genotype 4 HCV
NCT01838590Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sofosbuvir in hepatitis C (HCV) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response at 12 Weeks and Discontinuation due to Adverse Event. Started Mar 2013; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01838590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01838590.